



ASX Announcement

Wednesday 12th February 2014

Notification of 2014 Half Year Results

Medical technology company Cogstate (ASX:CGS) will lodge its Half Year Results on Tuesday 18th February.

An investor call will be held the following day, Wednesday 19th February at 10.30am (AEDT) hosted by Cogstate Chief Executive Officer Brad O'Connor. A presentation will be lodged prior to the call and accessible during the call via web access

<http://event.on24.com/r.htm?e=747102&s=1&k=A8DC16D8AE2752A5F0EEA90C2501D073>

Australian Participant Dial-In Numbers

Participants can dial either of the numbers below to join the call. They will need to quote ID **57997116**.

Toll-free: 1800 123 296

Toll: + 61 2 8038 5221 (can be used if dialing from international location)

International Participant Dial In Numbers

These numbers are toll-free dial in numbers for each country listed below. For countries not listed below, the Australian Toll number listed above can be dialed.

Canada	1855 5616 766
China	4001 203 085
Hong Kong	800 908 865
India	1800 3010 6141
Japan	0120 985 190
New Zealand	0800 452 782
Singapore	800 616 2288
United Kingdom	0808 234 0757
United States	1855 293 1544

For further information contact:

Rebecca Wilson
Buchan Consulting
+61 3 9866 4722 or 0417 382 391
rwilson@buchanewe.com.au

Brad O'Connor
CogState Chief Executive Officer
+61 3 9664 1300 or 0411 888 347
boconnor@cogstate.com

About CogState

CogState Ltd (ASX: CGS) is a multi-faceted cognitive assessment and training company, focused on the development and commercialisation of rapid, computerised tests of cognition (brain function). It has three distinct business units:

Clinical Trials: In the clinical drug trial market, CogState technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, CogState has secured agreements with top pharmaceutical companies including Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Johnson & Johnson, Novartis, Lundbeck, Daiippon Sumitomo, Targacept, Otsuka, and Servier.

Axon Sports: The mission of Axon Sports is to “protect and train the athletic brain”. Axon’s focus is to research, develop and deliver cutting edge tools to assess, monitor and improve the athletic brain.

Axon has been developing sport specific training products, initially focussed on American football and baseball, and the resulting technologies have now been launched within a small number of elite US college programs. In addition, the first of Axon’s consumer iPad apps was launched in 2012.

In the area of sports related concussion, CogState’s technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years. That technology is now marketed to consumers as Axon Sports. Current users of CogState/Axon Sports in Australia include, the AFL and NRL, whilst in the USA elite programs such as the NBA, WNBA, NHL as well as college programs such as University of Notre Dame, University of Michigan and University of Connecticut all use the Axon Sports system.

Healthcare: CogState’s efforts in the Healthcare market are initially focussed on providing tools to primary care physicians (General Practitioners) to assess cognition in patients and allow physicians to identify subtle changes that could be indicative of the early stage of a neurodegenerative disease, such as Alzheimer’s disease. In June 2012, CogState entered into an agreement with Merck Canada Inc. providing it with the exclusive right to market and promote the technology (marketed as Cognigram) to primary care physicians in Canada. First sales from Cognigram will occur in January 2013.